: Ranked as a "Best Buy" by Morningstar due to its "Wide Economic Moat" and dominance in the GLP-1 (weight loss/diabetes) sector.
: Holds a "Buy" rating with significant 1-year price target upside, largely due to its dominance in cystic fibrosis treatments. top pharma stocks to buy now
: Identified by Morningstar as one of the most undervalued wide-moat stocks, currently trading below its fair value. : Ranked as a "Best Buy" by Morningstar
: Frequently cited as a top pick for its leadership in the weight-loss market with Mounjaro and Zepbound . It remains the world's largest healthcare company by market cap. top pharma stocks to buy now
: Recognized for its strong clinical momentum in oncology and its leading HIV franchise, with consistent revenue growth reported recently. Global & High-Growth Tickers